IVIg

ApprovedSmall molecule

IVIg is one of 413 small molecule programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Approved.

Indications

Total Trials

Active Trials

412

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

Atrioventricular BlockActive, not recruiting

HypophosphatasiaActive, not recruiting

Neonatal SepsisActive, not recruiting

Cerebellar AtaxiaActive, not recruiting

Kidney TransplantActive, not recruiting

PneumoniaActive, not recruiting

MelanomaActive, not recruiting

Myasthenia GravisActive, not recruiting

Systemic SclerosisActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 3

Active, not recruiting

Atrioventricular BlockPhase 3

Active, not recruiting

HypophosphatasiaApproved

Active, not recruiting

Neonatal SepsisPhase 3

Active, not recruiting

Cerebellar AtaxiaPhase 2

Active, not recruiting

Kidney TransplantPhase 1

Active, not recruiting

PneumoniaPhase 3

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Myasthenia GravisApproved

Active, not recruiting

Systemic SclerosisPhase 2/Phase 3

Active, not recruiting

Showing 10 of 19 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

IVIg

Argenx

Approved

1 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Aldactone

Pfizer

Preclinical

1 7

Nexavar

Bayer

Preclinical

1 8

Singulair

AstraZeneca

Preclinical

1 9

Stivarga

Bayer

Preclinical

1 10

Aimovig

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Henoch-Schönlein Purpura

NCT03647852

Q1 2028

PreclinicalNot yet recruiting

Kawasaki Disease

NCT07686770

Q1 2029

Phase 3Recruiting

Chronic Inflammatory Demyelinating Polyneuropathy

NCT06290141

Q2 2029

Phase 3Recruiting

Atrioventricular Block

NCT04474223

Clinical

Trials by Indication[1]

Kawasaki Disease6 trials

Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial

Completed·FFudan University·Phase 3·NCT02298062·40 enrolled

KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)

Completed·UUniversity of California, San Diego·Phase 3·NCT03065244·105 enrolled

Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease

Withdrawn·—·Phase 3·NCT04535518

Show 3 more trials

Different Doses of IVIG for Kawasaki Disease

Completed·—·Phase 3·NCT02439996·404 enrolled

Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease

Active, not recruiting·—·Phase 3·NCT04078568·3,208 enrolled

Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease: An Exploratory Randomized Controlled Study

Not yet recruiting·CChildren's Hospital of Fudan University·Preclinical·NCT07686770·90 enrolled

Intravenous5 trials

Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)

Completed·HHaukeland University Hospital·Phase 2/3·NCT00231439·40 enrolled

Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections

Unknown status·SShanghai Changzheng Hospital·Phase 4·NCT05799716·40 enrolled

Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS)

Completed·MMansoura University Children Hospital·N/A·NCT01306578·41 enrolled

Show 2 more trials

Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS

Withdrawn·CCNS Onlus·Phase 2·NCT01769027

Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT00001550·20 enrolled

Pregnancy3 trials

Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss

Completed·TTabriz University of Medical Sciences·Phase 2·NCT03174951·50 enrolled

Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy

Recruiting·PPeking University People's Hospital·Phase 2·NCT06577909·100 enrolled

Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure

Completed·TTabriz University of Medical Sciences·Phase 2·NCT03174964·50 enrolled

Immune Thrombocytopenia3 trials

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Completed·—·Phase 3·NCT03939637·122 enrolled

A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients

Completed·MMcMaster University·Phase 3·NCT01621204·74 enrolled

A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia

Completed·WWeill Medical College of Cornell University·Phase 2/3·NCT00194987·102 enrolled

Kidney Transplant2 trials

IVIg to Treat BK Viremia in Kidney Transplant Recipients

Completed·MMassachusetts General Hospital·Phase 1·NCT02659891·16 enrolled

Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316

Completed· Novartis logo

Novartis·Phase 1·NCT02878616·8 enrolled

32 more indications

Treatment1 trial

IVIG (Gamunex-C) Treatment Study for POTS Subjects

Completed·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT03919773·30 enrolled

Desensitization1 trial

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

Completed·HHansa Biopharma AB·Phase 3·NCT04935177·64 enrolled

Neonatal Infection1 trial

Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection

Completed·NNICHD Neonatal Research Network·Phase 2/3·NCT01203345·2,416 enrolled

Systemic Sclerosis1 trial

Cardiac Safe Transplants for Systemic Sclerosis

Terminated·NNorthwestern University·Phase 2/3·NCT03593902·9 enrolled

Melanoma1 trial

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Unknown status·GGammaCan·Phase 2·NCT00294476·30 enrolled

Efficacy1 trial

Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG

Unknown status·AAzidus Brasil·Phase 3·NCT06089122·50 enrolled

Hypophosphatasia1 trial

Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 4·NCT06015750

COVID-191 trial

IVIG in Patients With Severe COVID-19 Requiring Mechanical Ventilation

Unknown status·SSharp HealthCare·Phase 4·NCT04616001·10 enrolled

Neonatal sepsis1 trial

Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis

Completed·HHormozgan University of Medical Sciences·Phase 3·NCT02954926·92 enrolled

Immune Checkpoint Inhibitor1 trial

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC

Withdrawn·VVA Office of Research and Development·Phase 1/2·NCT06064279

Cutaneous Lupus Erythematosus1 trial

IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus

Completed·UUniversity of California, Irvine·Phase 1·NCT01841619·16 enrolled

Infants1 trial

Post-bypass Prophylactic IVIG in Infants and Neonates

Completed·UUniversity of Alabama at Birmingham·N/A·NCT02043379·50 enrolled

Myasthenia Gravis1 trial

Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis

Completed·UUniversity Health Network, Toronto·Phase 4·NCT01179893·87 enrolled

Lung Transplantation1 trial

Intravenous Immunoglobulin (IVIG) in Lung Transplantation

Completed·—·Phase 2·NCT00115778·11 enrolled

Epilepsy1 trial

IVIG Treatment for Refractory Immune-Related Adult Epilepsy

Terminated·EEmory University·Phase 2·NCT01545518·20 enrolled

Multiple Sclerosis1 trial

Maximizing Outcome of Multiple Sclerosis Transplantation

Terminated·NNorthwestern University·Phase 3·NCT03342638·66 enrolled

Henoch-Schönlein Purpura1 trial

Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura

Recruiting·—·N/A·NCT03647852·150 enrolled

Pediatric1 trial

A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

Unknown status·IIMMUNOe Research Centers·Phase 4·NCT03348618·21 enrolled

Biomarkers1 trial

The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics

Active, not recruiting·DDobri Kiprov·Phase 3·NCT06534450·40 enrolled

Efficacy and Safety1 trial

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

Recruiting· Argenx logo

Argenx·Phase 3·NCT06920004·218 enrolled

First-line Treatment1 trial

Etoposide in the First-line Treatment of Adult EBV-HLH

Unknown status·—·Phase 3·NCT03742115·90 enrolled

CIDP1 trial

Transcriptome Analysis of the Peripheral Blood in CIDP

Unknown status·AAssistance Publique - Hôpitaux de Paris·N/A·NCT02404298·50 enrolled

Pneumonia1 trial

Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment

Completed·BBiopharma Plasma LLC·Phase 3·NCT04500067·76 enrolled

NMO Spectrum Disorder1 trial

Autologous Transplant To End NMO Spectrum Disorder

Withdrawn·NNorthwestern University·Phase 2/3·NCT03829566

Single Dose1 trial

Single Dose Study of ANX005 in Healthy Volunteers

Terminated·AAnnexon, Inc.·Phase 1·NCT03010046·27 enrolled

Cerebellar Ataxia1 trial

Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia

Completed·UUniversity of South Florida·Phase 2·NCT01350440·5 enrolled

Atrioventricular Block1 trial

Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

Recruiting·NNYU Langone Health·Phase 3·NCT04474223·1,300 enrolled

Randomised Controlled Trial1 trial

Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial

Completed·AAnders Perner·Phase 2·NCT02111161·100 enrolled

Neuropathy1 trial

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

Recruiting· Argenx logo

Argenx·Phase 3·NCT06742190·115 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT06290141·160 enrolled

Neonatal1 trial

Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06533098·50 enrolled

Unspecified1 trial

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

Active, not recruiting·KKanecia Obie Zimmerman·Phase 2·NCT06305793·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 51 trial records for IVIg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IVIg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IVIg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Argenx company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Argenx

IVIg

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Q1 2029

Q2 2029

Trials by Indication[1]

Kawasaki Disease6 trials

Intravenous5 trials

Pregnancy3 trials

Immune Thrombocytopenia3 trials

Kidney Transplant2 trials

Treatment1 trial

Desensitization1 trial

Neonatal Infection1 trial

Systemic Sclerosis1 trial

Melanoma1 trial

Efficacy1 trial

Hypophosphatasia1 trial

COVID-191 trial

Neonatal sepsis1 trial

Immune Checkpoint Inhibitor1 trial

Cutaneous Lupus Erythematosus1 trial

Infants1 trial

Myasthenia Gravis1 trial

Lung Transplantation1 trial

Epilepsy1 trial

Multiple Sclerosis1 trial

Henoch-Schönlein Purpura1 trial

Pediatric1 trial

Biomarkers1 trial

Efficacy and Safety1 trial

First-line Treatment1 trial

CIDP1 trial

Pneumonia1 trial

NMO Spectrum Disorder1 trial

Single Dose1 trial

Cerebellar Ataxia1 trial

Atrioventricular Block1 trial

Randomised Controlled Trial1 trial

Neuropathy1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Neonatal1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News